ARRDC4

Summary

ARRDC4 (arrestin domain containing 4, HGNC:28087) is a protein-coding gene on chromosome 15q26.2, encoding Arrestin domain-containing protein 4 (Q8NCT1). Functions as an adapter recruiting ubiquitin-protein ligases to their specific substrates.

Enables ubiquitin-like ligase-substrate adaptor activity. Involved in positive regulation of interferon-beta production and protein K63-linked ubiquitination. Acts upstream of or within positive regulation of ubiquitin-protein transferase activity. Located in endosome and plasma membrane.

Source: NCBI Gene 91947 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 92 total — 1 pathogenic
• MANE Select transcript: NM_183376

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28087
Approved symbol	ARRDC4
Name	arrestin domain containing 4
Location	15q26.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ36045
Ensembl gene	ENSG00000140450
Ensembl biotype	protein_coding
OMIM	619788
Entrez	91947

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000268042, ENST00000885035, ENST00000885036, ENST00000885037, ENST00000946276

RefSeq mRNA: 1 — MANE Select: NM_183376 NM_183376

CCDS: CCDS10377

Canonical transcript exons

ENST00000268042 — 8 exons

Exon	Start	End
ENSE00000943113	97965895	97966042
ENSE00000943114	97968014	97968116
ENSE00000943115	97969123	97969379
ENSE00000943116	97969883	97970045
ENSE00001163990	97970589	97970743
ENSE00001280411	97965600	97965666
ENSE00001280442	97960703	97961168
ENSE00001365782	97971131	97973833

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 97.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.1661 / max 338.8246, expressed in 1670 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
148787	19.1661	1670

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	97.61	gold quality
upper arm skin	UBERON:0004263	97.04	gold quality
skin of hip	UBERON:0001554	96.79	gold quality
ileal mucosa	UBERON:0000331	96.23	gold quality
spinal cord	UBERON:0002240	95.51	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.34	gold quality
decidua	UBERON:0002450	95.24	gold quality
kidney epithelium	UBERON:0004819	95.23	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.22	gold quality
colonic mucosa	UBERON:0000317	94.45	gold quality
corpus callosum	UBERON:0002336	94.13	gold quality
germinal epithelium of ovary	UBERON:0001304	94.12	gold quality
cardia of stomach	UBERON:0001162	93.38	gold quality
cardiac muscle of right atrium	UBERON:0003379	93.03	gold quality
nipple	UBERON:0002030	92.70	gold quality
cauda epididymis	UBERON:0004360	92.67	gold quality
amniotic fluid	UBERON:0000173	92.60	gold quality
epithelial cell of pancreas	CL:0000083	92.44	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.42	gold quality
caput epididymis	UBERON:0004358	92.20	gold quality
colon	UBERON:0001155	91.74	gold quality
parietal pleura	UBERON:0002400	91.66	gold quality
right uterine tube	UBERON:0001302	91.60	gold quality
large intestine	UBERON:0000059	91.59	gold quality
transverse colon	UBERON:0001157	91.29	gold quality
tibialis anterior	UBERON:0001385	91.23	gold quality
medulla oblongata	UBERON:0001896	90.90	gold quality
intestine	UBERON:0000160	90.61	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.56	gold quality
lower esophagus	UBERON:0013473	90.53	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-81608	yes	427.94
E-GEOD-83139	yes	318.61
E-ENAD-27	yes	8.94
E-ANND-3	yes	4.44
E-GEOD-75367	no	1693.80

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA2

miRNA regulators (miRDB)

196 targeting ARRDC4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-LET-7A-5P	99.98	72.29	1790

Literature-anchored findings (GeneRIF, showing 4)

• identification of variants in the ARRDC4 coding region; seven variants were identified; fifteen haplotypes were inferred; haplotypes form two clades (PMID:18307387)
• Txnip regulates cellular metabolism independent of its binding to thioredoxin and the arrestin domains are crucial structural elements in metabolic functions of alpha-arrestin proteins (PMID:19605364)
• data highlight new function of ARRDC4 in innate immunity, contributing to the better understanding about regulation of MDA5 activation after EV71 infection, and also suggest ARRDC4 may serve as a potential target for intervention of EV71-induced inflammatory response. (PMID:28594402)
• Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes. (PMID:38528189)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
mus_musculus	Arrdc4	ENSMUSG00000042659
rattus_norvegicus	Arrdc4	ENSRNOG00000010775
caenorhabditis_elegans		WBGENE00008843
caenorhabditis_elegans		WBGENE00009852
caenorhabditis_elegans		WBGENE00011052
caenorhabditis_elegans		WBGENE00011053
caenorhabditis_elegans		WBGENE00011054
caenorhabditis_elegans		WBGENE00012464
caenorhabditis_elegans		WBGENE00013043
caenorhabditis_elegans		WBGENE00014161
caenorhabditis_elegans		WBGENE00018060
caenorhabditis_elegans		WBGENE00018061
caenorhabditis_elegans		WBGENE00020612

Paralogs (5): ARRDC2 (ENSG00000105643), ARRDC3 (ENSG00000113369), ARRDC1 (ENSG00000197070), ARRDC5 (ENSG00000205784), TXNIP (ENSG00000265972)

Protein

Protein identifiers

Arrestin domain-containing protein 4 — Q8NCT1 (reviewed: Q8NCT1)

All UniProt accessions (1): Q8NCT1

UniProt curated annotations — full annotation on UniProt →

Function. Functions as an adapter recruiting ubiquitin-protein ligases to their specific substrates. Plays a role in endocytosis of activated G protein-coupled receptors (GPCRs). Through an ubiquitination-dependent mechanism also plays a role in the incorporation of SLC11A2 into extracellular vesicles. May play a role in glucose uptake. Participates in innate immune response by promoting IFIH1/MDA5 activation through interaction with TRIM65.

Subunit / interactions. Interacts with ADRB2. Interacts (via PPxY motifs) with ITCH, NEDD4L and WWP2. Interacts with AVPR2. Identified in a complex containing at least ARRDC4, AVPR2 and HGS. Interacts with SLC11A2; controls the incorporation of SLC11A2 into extracellular vesicles through an ubiquitination-dependent mechanism. Interacts with TRIM65.

Subcellular location. Early endosome. Cell membrane. Cytoplasmic vesicle.

Similarity. Belongs to the arrestin family.

RefSeq proteins (1): NP_899232* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011021	Arrestin-like_N	Domain
IPR011022	Arrestin-like_C	Domain
IPR014752	Arrestin-like_C_sf	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR050357	Arrestin_domain-protein	Family

Pfam: PF00339, PF02752

UniProt features (6 total): sequence variant 3, short sequence motif 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NCT1-F1	80.38	0.55

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 255 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, MARTINEZ_RB1_TARGETS_DN, GOBP_POSITIVE_REGULATION_OF_INTERFERON_BETA_PRODUCTION, ROZANOV_MMP14_TARGETS_UP, GOBP_CYTOKINE_PRODUCTION, WTGAAAT_UNKNOWN, NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON

GO Biological Process (6): protein transport (GO:0015031), protein ubiquitination (GO:0016567), positive regulation of interferon-beta production (GO:0032728), positive regulation of ubiquitin-protein transferase activity (GO:0051443), protein K63-linked ubiquitination (GO:0070534), extracellular vesicle biogenesis (GO:0140112)

GO Molecular Function (2): ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (7): cytoplasm (GO:0005737), endosome (GO:0005768), early endosome (GO:0005769), plasma membrane (GO:0005886), extracellular vesicle (GO:1903561), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
transport	1
intracellular protein localization	1
establishment of protein localization	1
protein modification by small protein conjugation	1
positive regulation of type I interferon production	1
interferon-beta production	1
regulation of interferon-beta production	1
ubiquitin-protein transferase activity	1
positive regulation of protein ubiquitination	1
positive regulation of catalytic activity	1
regulation of ubiquitin-protein transferase activity	1
protein polyubiquitination	1
cellular component biogenesis	1
enzyme-substrate adaptor activity	1
binding	1
intracellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1
endosome	1
membrane	1
cell periphery	1
extracellular region	1
vesicle	1
extracellular membrane-bounded organelle	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARRDC4	MLXIP	Q9HAP2	659
ARRDC4	TRIM65	Q6PJ69	585
ARRDC4	IFIH1	Q9BYX4	527
ARRDC4	SAG	P10523	520
ARRDC4	TRAPPC2L	Q9UL33	447
ARRDC4	PGPEP1L	A6NFU8	441
ARRDC4	WWP1	Q9H0M0	405
ARRDC4	IAPP	P10997	401
ARRDC4	NEDD4	P46934	401
ARRDC4	TMEM132B	Q14DG7	401
ARRDC4	ERO1B	Q86YB8	385
ARRDC4	DNAJB5	O75953	383
ARRDC4	ENO4	A6NNW6	381
ARRDC4	WWP2	O00308	379
ARRDC4	TXN2	Q99757	375
ARRDC4	FOXO1	Q12778	375

IntAct

7 interactions, top by confidence:

A	B	Type	Score
ARRDC4	WWP2	psi-mi:“MI:0914”(association)	0.530
ARRDC4	AVPR2	psi-mi:“MI:0915”(physical association)	0.400
WWP1	TP73	psi-mi:“MI:0914”(association)	0.350
SLC2A3	NRP2	psi-mi:“MI:0914”(association)	0.350

BioGRID (92): ADRB2 (Affinity Capture-Western), ARRDC4 (Affinity Capture-Western), AVPR2 (Affinity Capture-Western), ARRDC4 (Affinity Capture-Western), IFIH1 (Affinity Capture-Western), ARRDC4 (Affinity Capture-Western), TRIM65 (Affinity Capture-Western), ARRDC4 (Affinity Capture-MS), ARRDC4 (Affinity Capture-MS), XPOT (Affinity Capture-MS), PSMD13 (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), NDFIP1 (Affinity Capture-MS), SVIL (Affinity Capture-MS), PJA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1F4, A0A0G2JXN2, A2AWP8, A2RRH5, C9J798, O43374, O70277, O95294, P04629, P59926, Q0GA42, Q13368, Q14318, Q16512, Q29RM4, Q2HY40, Q2T9P3, Q2TBA3, Q5BIM1, Q5M7W1, Q5R5M3, Q5R811, Q5T7P8, Q5XIS9, Q62746, Q6PFQ7, Q6PFY8, Q7TNM2, Q7TP90, Q7Z4K8, Q8BG60, Q8BHT7, Q8BQC3, Q8C6N3, Q8CIW5, Q8IZ69, Q8NCT1, Q920N2, Q92546, Q925B4

Diamond homologs: A0A0B4J1F4, Q0VCA2, Q2HY40, Q5M7W1, Q5R5L7, Q5R811, Q6TXF1, Q7TP90, Q7TPQ9, Q8BG60, Q8NCT1, Q8TBH0, Q96B67, Q9D668, Q9H3M7, O45782, Q99KN1, B0BNL6, Q8N5I2, Q02805

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	70
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
395722	GRCh37/hg19 15q26.2-26.3(chr15:95202449-98779894)	Pathogenic

SpliceAI

733 predictions. Top by Δscore:

Variant	Effect	Δscore
15:97965665:GA:G	donor_gain	1.0000
15:97965667:G:GG	donor_gain	1.0000
15:97965886:T:A	acceptor_gain	1.0000
15:97965892:CA:C	acceptor_loss	1.0000
15:97965893:A:AG	acceptor_gain	1.0000
15:97965893:AGACC:A	acceptor_loss	1.0000
15:97965894:G:GA	acceptor_gain	1.0000
15:97965894:GA:G	acceptor_gain	1.0000
15:97965894:GAC:G	acceptor_gain	1.0000
15:97965894:GACC:G	acceptor_gain	1.0000
15:97965894:GACCT:G	acceptor_gain	1.0000
15:97966038:TATTA:T	donor_gain	1.0000
15:97966039:ATTA:A	donor_gain	1.0000
15:97966040:TTA:T	donor_gain	1.0000
15:97966041:TA:T	donor_gain	1.0000
15:97966042:AG:A	donor_loss	1.0000
15:97966043:G:GG	donor_gain	1.0000
15:97966044:T:G	donor_loss	1.0000
15:97968001:T:TA	acceptor_gain	1.0000
15:97968011:A:AG	acceptor_gain	1.0000
15:97968012:A:AG	acceptor_gain	1.0000
15:97968013:G:GG	acceptor_gain	1.0000
15:97969118:TTTA:T	acceptor_loss	1.0000
15:97969120:TA:T	acceptor_loss	1.0000
15:97969121:A:AG	acceptor_gain	1.0000
15:97969121:A:AT	acceptor_loss	1.0000
15:97969122:G:GT	acceptor_gain	1.0000
15:97969122:GGA:G	acceptor_gain	1.0000
15:97969122:GGAGA:G	acceptor_gain	1.0000
15:97969375:TAGCT:T	donor_gain	1.0000

AlphaMissense

2700 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:97968075:T:A	V195D	1.000
15:97969157:T:A	N220K	1.000
15:97969157:T:G	N220K	1.000
15:97969296:T:A	W267R	1.000
15:97969296:T:C	W267R	1.000
15:97965644:T:C	F118L	0.999
15:97965645:T:C	F118S	0.999
15:97965646:T:A	F118L	0.999
15:97965646:T:G	F118L	0.999
15:97965927:G:A	G136E	0.999
15:97965938:T:G	Y140D	0.999
15:97968087:C:A	A199D	0.999
15:97969138:T:A	I214N	0.999
15:97969143:G:C	A216P	0.999
15:97969144:C:A	A216E	0.999
15:97969180:C:A	P228Q	0.999
15:97969185:G:C	A230P	0.999
15:97969186:C:A	A230D	0.999
15:97969188:G:C	A231P	0.999
15:97969192:T:A	I232N	0.999
15:97969298:G:C	W267C	0.999
15:97969298:G:T	W267C	0.999
15:97960980:G:A	G40E	0.998
15:97965651:T:C	F120S	0.998
15:97965911:T:C	F131L	0.998
15:97965913:T:A	F131L	0.998
15:97965913:T:G	F131L	0.998
15:97965939:A:C	Y140S	0.998
15:97968081:T:C	L197P	0.998
15:97968104:G:A	G205R	0.998

dbSNP variants (sampled 300 via entrez): RS1000098529 (15:97968961 G>C), RS1000359411 (15:97966661 A>G), RS1000711304 (15:97965424 GAC>G,GACAC,GACACAC,GACACACAC), RS1000797766 (15:97963437 T>A), RS1001107014 (15:97970378 T>C), RS1001227368 (15:97968536 C>A), RS1001523307 (15:97960494 A>G), RS1001558092 (15:97970658 C>G,T), RS1002016975 (15:97962988 T>A,C), RS1002261569 (15:97959320 T>C), RS1002316302 (15:97970511 T>G), RS1002428679 (15:97964260 C>T), RS1002451286 (15:97963348 A>G), RS1002680994 (15:97960733 C>G,T), RS1002902952 (15:97966843 T>C)

Disease associations

OMIM: gene MIM:619788 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001343_13	Fat distribution (HIV)	8.000000e-07
GCST004569_2	Neuroticism	1.000000e-06
GCST009276_8	Response to placebo treatment in childhood asthma (FVC change)	7.000000e-06
GCST011696_10	Alzheimer’s disease	2.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004341	body fat distribution
EFO:0008344	response to placebo
EFO:0010339	FVC change measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

84 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	5
Valproic Acid	affects expression, increases expression	5
Benzo(a)pyrene	increases expression	4
Cyclosporine	increases expression	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	4
(+)-JQ1 compound	decreases expression, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	3
Cisplatin	affects cotreatment, decreases expression, increases expression	3
Estradiol	increases expression	3
Aflatoxin B1	increases expression, affects expression, decreases expression, decreases methylation	3
methylmercuric chloride	decreases expression	2
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression, decreases expression	2
entinostat	affects cotreatment, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Rotenone	decreases expression	2
Silicon Dioxide	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
OTX015	increases expression	1
mivebresib	increases expression	1
Esketamine	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
lead acetate	increases expression	1
trichostatin A	increases expression	1
thallium sulfate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_F1P1	HyCyte HCT 116 KO-hARRDC4	Cancer cell line	Male

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery